Combination of Tocilizumab, IVIG and CRRT in severe patients with novel coronavirus pneumonia (COVID-19)

The therapeutic efficacy of combination of Tocilizumab, IVIG and CRRT in sever patients with novel coronavirus pneumonia (COVID-19)

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030442

Enrollment

Unknown

Registered

2020-03-02

Start date

2020-03-05

Completion date

Unknown

Last updated

2020-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus Disease 2019

Interventions

Case series:Combination of Tocilizumab, IVIG and CRRT

Eligibility

Sex/Gender

Male

Age

20 Years to 90 Years

Inclusion criteria

Inclusion criteria: severe case of COVID-19

Exclusion criteria

Exclusion criteria: Allergy to any medicine Pregnancy

Design outcomes

Primary

Measure	Time frame
Inhospital time;	—

Secondary

Measure	Time frame
Survival rate;	—

Contacts

Public ContactMa Xiaorong

the Second Affiliated hospital of Xi'an Jiaotong University

maxr0910@163.com+86 13992856156

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026